A review on novelty and potentiality of vaginal drug delivery

International Journal of PharmTech Research

Volumn 3, Issue 2, 2011, Pages 1033-1044

  Choudhury, Ananta ^a   Das, Sujoy ^a   Kar, Mousumi ^a  

^a GRY Institute of Pharmacy   (India)

Author keywords

HIV; Intravaginal delivery; Vagina; Vaginal formulations

Indexed keywords

8 QUINOLINOL SULFATE; 8 QUINOLINOL SULFATE PLUS ACETIC ACID PLUS GLYCEROL PLUS RICINOLEIC ACID; ACETIC ACID; ADVANTAGES; CLOTRIMAZOLE; ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETONOGESTREL; GESTAGEN; GONADORELIN; INSULIN; LEUPRORELIN; LEVONORGESTREL; METRONIDAZOLE; MICONAZOLE NITRATE; NONOXINOL 9; NORETHISTERONE ACETATE; PROGESTERONE; PROSTAGLANDIN E2; RELAXIN; RICINOLEIC ACID; TENOFOVIR; TIOCONAZOLE; TRIVAGIZOLE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; CANDIDIASIS; CONSTIPATION; CONTRACEPTION; CREAM; DIARRHEA; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; GEL; HISTOLOGY; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; LIVER METABOLISM; MASTALGIA; MEMBRANE PERMEABILITY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; SIDE EFFECT; SKIN IRRITATION; UNSPECIFIED SIDE EFFECT; VAGINA RING; VAGINA SECRETION; VAGINITIS; VASCULARIZATION; WEIGHT GAIN;

EID: 84863396526     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Alexander N.J., Banker E., Kaptein M., Karck U., Miller L., & Zampaglione E., Why consider vaginal drug administration?, Fertility and Sterility. 2004, 82: 1-12.
2. Song Y., wang Y., Thakur R., Medidan V.M. & Michniak B., Mucosal drug delivery: membranes, methodologies and applications, Crit. Rev.Ther. Drug Carrier. Syst., 2004, 21: 195-256.
3. Weber J., Desai K. & Darbyshire J., The development of vaginal microbicides for the prevention of HIV transmission, PLOS Medicine. 2005, 2: 392-395.
4. Katz D.F., Dunmire E. N., Henderson M. H., Owen D.H. & Plenys A.M., Applications of biomedical engineering in reproductive biomedicine: Sensing and drug delivery to the lower female reproductive tract, Eng. Med. Boil. Soc., 1997, 30: 2656-2658.
5. Ansel H.C., Popovich N.G. & Allen L.V., Pharmaceutical dosage forms and drug delivery, Williams & Wilkins, Melvern, 1985.
6. Sassi A.B., Mccullough K.D., Cost M.R., Hillier S.L. & Rohan L.C, Permeability of tritiated water through human cervical and vaginal tissue, J Pharm. Sci., 2004, 93: 2009-2016.
7. Okada H., Vaginal route of peptide & protein delivery in Peptide and protein drug delivery, (V.H.L. Lee, eds.) Marcel Dekker, New York, 1991, pp.633-666.
8. Vermani, K. & Garg S., The scope of potential of vaginal drug delivery. Research Focus. 2000, 3: 359-364.
9. Hussain A. & Ahsan F., The vagina as a route of systemic drug delivery, J Controlled Release, 2005, 103: 301-313.
10. Woolfson A.D., Melcolm R.K. & Gallagher R., Drug delivery by the intravaginal route, Crit. Rev. Ther. Drug Carr. Syst, 2000, 17: 509-555.
11. Washington N., Washington C. & Wilson C.G., Vaginal and intrauterine drug delivery in Physical pharmaceutics: barriers to drug absorption, (N. Washington, C. Washington & C.G. Wilson, eds.) Taylor and Francis, Landon, 2001, pp. 271-281.
12. Richter K. & Frick H., Anatomy of visceral fascia of the pelvis from the didactical view point (In German), Geburtshilfe frauenheilkd, 1985, 45: 282-287.
13. Funt M.I., Thompson J.D. & Brich H., Normal vaginal axis, South Med. J., 1978, 71: 1534-35.
14. Richardson J.L. & Illum L., Preparation enhancement for polypeptides through epithelia, Adv. Drug Deliv. 1992, 8: 341-366.
15. Platzorer W., poisel W. & hafez E.S.E., Functional anatomy of human vagina, in Human reproductive medicine: The human vagina, (E.S.E. Hafez, T.N. Evans, eds.) Nath Wolland Publishing, 1978, New York, pp. 39-54.
16. Herbst A.L., Mishell D.R., Stenchever M.A. & Droegemueller W., Comprehensive gynecology. Mosby year book, New York, 1982.
17. Paavonen J., Physiology & ecology of the vagina. Scand. J. Infect. Dis., 1983, 40: 31-35.
18. Carlstrom K., Pschera H. & Lunell N.O., Serum levels of estrogen, progesterone, follicle-stimulating hormone and sex hormone-binding globulin during simultaneous vaginal administration of 17- β-oestradiol and progesterone in the pre and postmenoposse, Maturitas., 1988, 10: 307-316.
19. Semmens J.P., Tsai C.C., Semmens E.C. & Loadholt C.B., Effects of estrogen therapy on vaginal physiology during menopause, Obstet Gynecol., 1985, 66: 8-15.
20. Wagner G. & Levin R. J., Vaginal fluid in Human reproductive medicine: the human vagina, (E.S.E. Hafez, T.N. Evans, eds.) North Holland publishing, New York, 1978, pp. 121-137.
21. Soper D.E., Genitourinary infections and sextually transmitted disease, in "Novak's gynecology", (S. Berek, E.Y. Adashi, P.A. Hillard, eds.) Willams & Wilkins, pp 132-157
22. Pschera H., Hjerpe A. & Carlstrom, Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17-β and progesterone in postmenopausal woman, Gynecol. Obstet. Invest, 1989, 27: 204-207.
23. Hwang S., Owada E., Suhardja L.H.U., Flynn G.L. & Higuchi W.I., Systems approach to vaginal delivery of drug: 4 methodology for determination of membrane surface pH., J Pharm Sci., 1977, 66: 778
24. Katz D.F. & Duna E.N., Cervical mucus: problems and opportunities for drug delivery via the vagina & cervix, Adv.Drug Deliv. Rev., 1993, 11: 385-401.
25. Johnson T.A., Greer I.A., Kelly R.W. & Calder A.A., The effect of pH on release of PGE2 from vaginal & endocervical preparation for induction of labour: and in-vitro study, Br. J. Obstet. Gynaecol., 1992, 99: 877-880.
26. Owen D.H., Dunmire E.N., Planys A.M. & Katz D.F., Factors influencing nonoxynol-9. J control release, 1996, 39: 93.
27. Brannon P.L., Novel vaginal drug release applications, Adv. Drug Rev., 1992, 11: 169-177.
28. Johnson V.E. & Masters W.H., Intravaginal contraceptive study phase-I anatomy. West. J. Surg. Obstet. Gynecol., 1962, 70: 202-207.
29. Chatterton B.E., Penglis S., Kovacs J.C., Presnell B. & Hunt B., Retention & distribution of two 99m-Tc-DTPA labeled vaginal dosage form, Int. J. Pharm., 2004, 271: 137-143.
30. Du Bouchet L., McGreger J.A., Ismail M., A pilot study of metronidazole vaginal get versus oral metronidazole treatment of trichomonas vaginalis vaginitis, Sex Transm. Dis., 1998, 25: 176-179.
31. Francois M., Snoeck E., Putteman P., Wouter F., Proost E.D., Deluet U., Peeter J. & Brewster M.E., A mucoadhesive, cyclodextrin based vaginal cream formulation itraconazole, AAPS Pharm Sci., 2003, 5: 1-5.
32. Mandal T.K., Swelling controlled release system for the vaginal delivery of miconazole, Eur. J. Pharm. Biopharm., 2000, 50: 337-343.
33. Owen D.H., Dunmire E.N., Plamys A.M. & Katz D.F., Factors influencing nonoxynol-9 permeation and bioactivity in cervical mucus, J. Control Release., 1999, 60: 23-34.
34. Dcruz U.J., Zhu Z.H., Yiv S.H., Chen C.L., Waurzyniak B. & Uckun F.M., WHI-05, a novel bromi-methoxy substituted phenyl phosphate derivative of zidovudine, is a dual action spermicide with potent anti HIV activity. Contraception, 1999, 59: 319-331.
35. Neurath A.R., Srick N. & Li Y., Water dispersible microbicidal cellulose acetate phthalate film, BMC Infect. Dis., 2003, 3: 27.
36. Fichora R.N., Zhou F., Ratnan V., Atanassova V., Giang S., Strick N. & Neurath A.R., Anti human immune deficiency virus. Type I microbicides cellulose acetate 1, 2 benzene dicarboxylate in a human in-vitro model of vaginal inflammation, Antimicrobial Agents Chemother., 2005, 49(1): 323-325.
37. Mayer K.H., Karim S.A. & Kelly C., The safety and tolerability of a novel vaginal microbicides. PRO 2000/5 gel in sexually active HIV uninfected and abstinent HIV infected women, AIDS, 2003, 17: 321
38. Manson K.H., Wyand M.S., Miller C. & Neurath A.R., Effect of cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkey, Antimicrob Agents Chemither, 2000, 44(11): 3199-3302.
39. Wassen K.S., Holngren L., Jerborn M. & Lycke N., Local intra vaginal vaccination of the female genital tract. Scand. J. Immunol, 1996, 44: 408-414.
40. Shetty A., Livingston I., Acharya S. & Templeton A., Vaginal prostaglandin E2 gel versus tablet in the induction of labour at term- a retrospective analysis, J. Obstet. Gynaecol, 2004, 24: 243-246.
41. Hall R., Gardea D.M. & Harlan F., Oral versus vaginal misoprostol for labor induction. Obstet. Gynecol, 2002, 99: 1044-1048.
42. Shetty A., Livingstone I., Achrya S., Rice P., Danielian P. Oral misoprostol (100μg) versus vaginal misoprostol (25μg) in term labor induction: a randomized comparison. Acta Obstet. Gynecol. Scand, 2003, 82: 1103-1106.
43. Chang J.Y., Oh V.K., Kong H.S., Kim E.J., Jang D.D., Nan K.T. & Kim C.K., Prolonged antifungal effect of clotrimazole-containing mucoadhesive thermosensitive gels on vaginitis, J. control. Release, 2002, 82: 39-50.
44. Alam A.M., Ahmad J.F., Khan I.Z., Khar K.R. & Ali M., Development and evaluation of acid buffering bioadhesive vaginal tablet for mixed vaginal infections. AAPS Pharm Sci. Tech., 2007, 8(4): E1-E8.
45. Ceschel G.C., Maffei P., Borgia S.L., Ronchi C. & Rossi S., Development of mucoadhesive dosages form for vaginal administration, Drug Dev. Ind. Pharm., 2001, 27: 541-547.
46. Kamel A.E., Sokar M., Nagger V. & Gamal S.A., Chitosan and sodium alginate based bioadhesive vaginal tablets, AAPS Pharm Sci., 2002, 4(4): 1-7.
47. Sharma G., Jain S., Tiwary A.K. & Kaur G, Once daily bioadhesive vaginal clotrimazole tablet: design and evaluation, Acta Pharm., 2006, 56: 337-345.
48. Roumen F.J.M.E. & Dieben T.O.M., Clinical acceptability of an ethylene vinyl-acetate nonmedicated vaginal ring, Contraception, 1999, 5: 59-62.
49. Novak A., Loge C., Ebetz L. & Maulen E.A., The combined contraceptive vaginal ring, nuva ring: an international study of user acceptability, Contraception, 2003, 67: 187-194.
50. Priet J., Lamontagne J., Bestman-smith J., Roy S., Gourde P., Desormeaur A., Omar R.F., Juhasz J. & Bergeron M.G., Invitro and invivo evaluation of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses, J. Clin. Microbiol, 2000, 38: 110-119.
51. Richardson J.L. & Armstrong T.I., Vaginal delivery of calcitonin by hyaluronic acid formulations, in Bioadhesive drug delivery systems: fundamentals, novel approaches and development, (E. Mathiowitz, D.E. Chickering III, C.M. Lehr, eds.) Marcel Dekker, New York, 1999, pp.563-599.
52. Lee C.H., Anderson M. & Chein Y.W., The characterization of in-vitro spermicidal activity of chelating agent on human sperm, J. Pharm. Sci., 1996, 85: 649-654.
53. Lee C.H., Bagdon R. & Chien Y.W., Comparative in-vitro spermicidal activity and synergistic effect of chelating agents with nonoxynol-9 on human sperm functionality, J. Pharm. Sci., 1996, 85: 91-95.
54. Vermani K., Garg S. & Zaneveld L.J.Z., Assemblies for in-vitro measurement of bioadhesive strength and relention characteristics is simulated vaginal environment, Drug Dev. Ind. Pharm., 2002, 28: 1133-1146.
55. Herold B.C., Bourne N., Marcellino D., Kirkpatrick R., Strauss D.M., Zaneveld L.J., Waller D.P., Anderson R.A., Chany C.J., Borham B.J., Stanberry L.R. & Cooper M.S., Poly (sodium 4-styrene sulfanate): an effective candidate topical antimicrobial for the prevention of sexually transmited disease, J. Infed. Dis., 2000, 181: 770-773.
56. Zaneveld L.J., Waller D.P., Anderson R.A., Chany C., Rencher W.F., Feathergill K., Diao K., Doncel G.F., Herold B. & M. Cooper M., Efficacy and safety of a new vaginal contraceptive antimicrobial formulation containing high molecular weight poly (sodium-4-styrene sulfonate). Biol. Reprod, 2002, 66: 886-894.
57. Smith M., TMC 120 Vaginal ring premising as microbicides carrier, XVI international conference, Toronto Canada, 2006.
58. Keller M.J., Tuyam A. & Carluc M.J., Topical microbicides for the prevention of genital herpes infection. J. Antimicrob. Chemother, 2005, 55(4): 420-423.
59. Boskey E.R., Cone R.A., Whaley K.J. & Moench T.R., Origin of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source, Hum. Reprod, 2001, 16(9): 1809-1813.
60. Stone A., MICROBICIDES: a new approach to preventing HIV and other sexually transmitted infections, Nature reviews, 2002, 122-130.
61. Crambie R., Kawasaki K., Hojo K. & Laurence J., Peptides derived from salivary thrombospondin-1 replicates its anti HIV effect: potential role in microbicide development, J. AIDS, 2001, 27(1): 91-93.
62. Neves J. D, Bahia M.F., Gels as vaginal drug delivery systems. International Journal of Pharmaceutics, 2006, 318, 1-14.